684 related articles for article (PubMed ID: 24004659)
1. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
Feldman GJ; Edin A
Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
[TBL] [Abstract][Full Text] [Related]
4. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
Rhee CK; Yoshisue H; Lad R
Adv Ther; 2019 Mar; 36(3):495-519. PubMed ID: 30742242
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
Feldman GJ; Sousa AR; Lipson DA; Tombs L; Barnes N; Riley JH; Patel S; Naya I; Compton C; Alcázar Navarrete B
Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
[TBL] [Abstract][Full Text] [Related]
6. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
Feldman G; Walker RR; Brooks J; Mehta R; Crater G
Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
Ray R; Tombs L; Naya I; Compton C; Lipson DA; Boucot I
Pulm Pharmacol Ther; 2019 Aug; 57():101802. PubMed ID: 31096036
[TBL] [Abstract][Full Text] [Related]
9. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
[No Abstract] [Full Text] [Related]
10. Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.
Kelly E
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):403-13. PubMed ID: 24909949
[TBL] [Abstract][Full Text] [Related]
11. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol.
Malerba M; Morjaria JB; Radaeli A
Int J Chron Obstruct Pulmon Dis; 2014; 9():687-95. PubMed ID: 25061288
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
Maleki-Yazdi MR; Kaelin T; Richard N; Zvarich M; Church A
Respir Med; 2014 Dec; 108(12):1752-60. PubMed ID: 25458157
[TBL] [Abstract][Full Text] [Related]
14. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.
Albertson TE; Bowman WS; Harper RW; Godbout RM; Murin S
Int J Chron Obstruct Pulmon Dis; 2019; 14():1251-1265. PubMed ID: 31239659
[TBL] [Abstract][Full Text] [Related]
16. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
Kalberg C; O'Dell D; Galkin D; Newlands A; Fahy WA
Drugs R D; 2016 Jun; 16(2):217-27. PubMed ID: 27028749
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
[TBL] [Abstract][Full Text] [Related]
18. Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines.
Davidson JF; Donohue JF; Ohar JA
Expert Opin Drug Saf; 2015 Feb; 14(2):317-24. PubMed ID: 25598422
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
Bateman ED; Mahler DA; Vogelmeier CF; Wedzicha JA; Patalano F; Banerji D
Expert Rev Respir Med; 2014 Jun; 8(3):357-79. PubMed ID: 24802656
[TBL] [Abstract][Full Text] [Related]
20. Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA.
Hahn B; Hull M; Blauer-Peterson C; Buikema AR; Ray R; Stanford RH
Respir Med; 2018 Jun; 139():65-71. PubMed ID: 29858004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]